NED Biosystems Revenue and Competitors
Estimated Revenue & Valuation
- NED Biosystems's estimated annual revenue is currently $1.6M per year.
- NED Biosystems's estimated revenue per employee is $155,000
Employee Data
- NED Biosystems has 10 Employees.
- NED Biosystems grew their employee count by -9% last year.
NED Biosystems's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Founder and Executive Chairman | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | CFO & COO | Reveal Email/Phone |
5 | Director Business Operations | Reveal Email/Phone |
NED Biosystems Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is NED Biosystems?
Pursuing No Evidence of Disease NED Biosystems™ is a clinical-stage biotech company developing innovative treatments unlike most available today. We begin with a focus on patients and their families. NED seeks to dramatically improve patients’ outcomes with therapies that lack the toxicity and side effects of today’s treatments, allowing patients a high quality of life. NED has initiated a multi-pronged approach to treating cancer through NED-170, the patented investigational cancer product that affects four key processes that advance all late-stage cancer with an anticipated well-tolerated safety profile. The same four processes that drive cancer are integral to COVID-19. NED has rapidly deployed its translational multi-pronged approach to the development of a prophylactic and treatment for COVID-19. NED-260, an investigational product, is designed to be the first orally administered combination for prophylaxis and treatment against COVID-19.
keywords:N/A
N/A
Total Funding
10
Number of Employees
$1.6M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.9M | 10 | N/A | N/A |
#2 | $0.9M | 10 | N/A | N/A |
#3 | $0.9M | 10 | N/A | N/A |
#4 | $0.9M | 10 | N/A | N/A |
#5 | $0.8M | 10 | N/A | N/A |